Med. praxi. 2021;18(1):71-74 [Klin Farmakol Farm. 2020;34(3):142-145]

An unexpected cause of delirium

MUDr. Jiří Holý, Ph.D.1, MUDr. Martin Holý1, MUDr. Zdeněk Beneš2, MUDr. Marie Pešková1
1 Interní oddělení Nemocnice České Budějovice, a. s.
2 Oddělení úrazové a plastické chirurgie Nemocnice České Budějovice, a. s.

The authors document case history of an 70 years old male patient with hypertension, diabetes mellitus of 2nd type and dyslipidaemia, after a potentially curative treatment of carcinoma of the prostate gland, suffering from a contusion of right lower extremity followed by a lesion of nervus ischiadicus. The patient took glimepiride 2 mg daily, rosuvastatin 20 mg daily, ramiprilum 5 mg and amlodipine 10 mg in fixed- dose combination and escitalopram 10 mg daily before an admission. The wounded man suffers from the development of rhabdomyolysis with acute renal failure. Repeated delirious status caused by hypoglycaemia appears by the patient during the hospitalisation, for the first time 25 hours after the last dose of glimepiride. These status were treated repeatedly by 40% glucosis as bolus and then continuous intravenous infusion therapy of glucosis, lasted 7 days in general. The patient was also treated by concentrates of erythrocytes, intermittent haemodialysis and antibiotics, he was transfered in a stable status. We explain repeated hypoglycaemia by a cumulation of metabolite of glimepiride owing to acute renal failure. The clinic manifestation of hypoglycaemia was also interesting, it was always delirium with aggression.

Keywords: diabetes mellitus, rhabdomyolysis, acute renal failure, hypoglycaemia, glimepiride.

Published: April 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holý J, Holý M, Beneš Z, Pešková M. An unexpected cause of delirium. Med. praxi. 2021;18(1):71-74.
Download citation

References

  1. Češka R, Tesař V, Lukáš M, et al. Interna. 3. vydání. Praha: Triton, 2020: 1032.
  2. Souček M, Špinar J, Vorlíček J, et al. Vnitřní lékařství. 1. vydání. Praha: Grada Publishing, a. s., 2011; 1577.
  3. Chan JC, Cockram CS, Critchley JA. Drug‑induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996; 15(2): 135-157. Go to original source... Go to PubMed...
  4. Sulfonylureas [online]. [cit. 2020-09-26]. Dostupné z: https://www.diabetes.org/diabetes/medication‑management/oral‑medication/what‑are‑my‑options.
  5. Škrha J, Šváb J, Keil R. Inzulinom - diagnostika a léčba. DMEV Supplementum 2006; (1): 34-38.
  6. Karvunidis T, Kroužecký A, Raděj J, et al. Pacientka s těžkou protrahovanou hypoglykemií. Anest. intenziv. Med. 2009; 20(4): 200-202.
  7. Škrha J. Hypoglykemický syndrom. 1. vydání Praha: Grada, 2001; 114.
  8. Souhrn údajů o přípravku Amaryl 2 mg a 3 mg [online]. [cit. 2020-09-26]. Dostupné z: www.sukl.cz/modules/medication/search.php.
  9. Sulfonylureas [online]. [cit. 2020-09-26]. Dostupné z: https://www.fda.gov/consumers/womens‑health‑topics/women‑and‑diabetes‑diabetes‑medicines.
  10. Otto C, Richter WO. Hypoglycaemia. Symptoms, differential diagnosis, therapy. Fortschr Med. 1997; 115(6): 37-39.
  11. Kiriyama A, Kimura S, Banba C, Yamakawa M, Yajima R, et al. (2017) Pharmacokinetic‑Pharmacodynamic Analyses of Anti‑diabetes, Glimepiride: Comparison of the Streptozotocin‑Induced Diabetic, GK, and Wistar Rats. J Drug Metab Toxicol 8: 229. doi: 10.4172/2157-7609.1000229. Go to original source...
  12. Rosenkranz B, Profozic V, Metelko Z, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia (1996) 39: 1617-1624. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.